Venture
Biolinq Inc
Latest Form D 2025-03-21- CIK 1685406
- State CA
- Biotechnology
- 8 Form D offerings since 2016-09-28
- Total sold
- $247M
- across 8 offerings
- Rounds
- 8
- Form D offerings since 2016-09-28
- Latest round
- $90M
- 2025-03-21 · 021-541825
- Investors
- 45
- on the latest round
Connected
named in its Form D filingsRound timeline
amount sold · by first filed2025-03-21 · $90M
- 2016-09-28$450K021-271446
- 2017-11-27$8.1M021-299492
- 2019-03-20$3M021-335310
- 2020-04-07$3.6M021-364474
- 2021-03-23$5.2M021-393191
- 2021-09-17$77.9M021-413731
- 2023-12-26$59.1M021-500681
- 2025-03-21$90M021-541825
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($90M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-541825 | First filed2025-03-21 | Latest2025-03-21 | Sought$100M | Sold$90M | Investors45 | Exemptions506(b) |
| 021-500681 | First filed2023-12-26 | Latest2024-09-13 | Sought$59.1M | Sold$59.1M | Investors43 | Exemptions506(b) |
| 021-413731 | First filed2021-09-17 | Latest2022-06-01 | Sought$106M | Sold$77.9M | Investors62 | Exemptions506(b) |
| 021-393191 | First filed2021-03-23 | Latest2021-03-23 | Sought$6M | Sold$5.2M | Investors21 | Exemptions506(b) |
| 021-364474 | First filed2020-04-07 | Latest2020-07-07 | Sought$10M | Sold$3.6M | Investors17 | Exemptions506(b) |
| 021-335310 | First filed2019-03-20 | Latest2019-03-20 | Sought$3M | Sold$3M | Investors9 | Exemptions506(b) |
| 021-299492 | First filed2017-11-27 | Latest2017-11-27 | Sought$13.1M | Sold$8.1M | Investors17 | Exemptions506(b) |
| 021-271446 | First filed2016-09-28 | Latest2016-09-28 | Sought$750K | Sold$450K | Investors5 | Exemptions506(b) |
Who backs Biolinq Inc, inferred from co-filings, and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2025-03-21
| Name | Relationship |
|---|---|
| RICHARD YANG | RelationshipExecutive Officer, Director |
| CHRIS DIMITROPOULOS | RelationshipDirector |
| DEREK RAPP | RelationshipDirector |
| THAD JOHNSON | RelationshipDirector |
| DAN BRADBURY | RelationshipDirector |
| ZINA AFFAS BESSE | RelationshipDirector |
| DAVID BERRY | RelationshipDirector |
| JARED AFFAS TANGNEY | RelationshipExecutive Officer |
| DAVID ARIDA | RelationshipExecutive Officer |
Sales compensation
Named in Item 12 of its Form D filings
| Recipient | CRD | Broker-dealer | Offerings |
|---|---|---|---|
| J.P. Morgan Securities LLC | CRD79 | Broker-dealer— | Offerings1 |
| Thomas Mark Cibotti | CRD4672417 | Broker-dealerCovington Associates, LLC · CRD 127437 | Offerings1 |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- California (CA)
- Exemptions
- Rule 506(b)
- First filed
- 2016-09-28
- Latest filing
- 2025-03-21
Who backs Biolinq Inc
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗